A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults

Phase 3

RSVpreF & Herpes ZosterA Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults

Sponsor:

Pfizer

Code:

NCT06890416

Conditions

Respiratory Syncytial Virus (RSV)

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Accepted

Interventions

RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE

HZ/su VACCINE

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-24. This information was provided to ClinicalTrials.gov by Pfizer on 2025-05-31.